Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Sanofi-aventis

Hoechst Aktiengesellschaft

Sanofi

Gerhard Jaehne

Martin Bickel

Matthias Gossel

Heiner Glombik

Wendelin Frick

Andreas Lindenschmidt

Hubert Heuer

Stefanie Flohr

Volker Krone

Werner Kramer

Karl Schoenafinger

Hans-Ludwig Schaefer

Georg Tschank

Christian Buning

Ulrich Werner

Elisabeth Defossa

Olaf Ritzeler

Karl Geisen

Hans-Ludwig Schäfer

Holger Wagner

Hans-Jochen Lang

Hans Jochen Lang

Werner Krame

Siegfried Stengelin

Lothar Schwink

Irvin Winkler

Gerd Geisslinger

Guenter Billen

Martin Michaelis

Karl Rudolphi

Hans-Georg Schaible

Holger Gaul

Eric Galia

Andreas W Herling

David William Will

Michael R Myers

Hans Ulrich Stilz

Thomas Klabunde

Guenter Mueller

Antony Bigot

Joerg Habermann

Matthias Helsberg

Heiner Jendralla

Bernhard Neises

Bernd Junker

Theodor Andreas Wollmann

David Rigal

Franz Jakob Hock

Matthias G Ssel

Gerhard Gross

Thomas Scholl

Siegfird Stengelin

Elizabeth Defossa

Christian Bunning

The present invention relates to the use of I&#x3ba;B-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

Use of I&#x3ba;B-kinase inhibitors in pain therapy

The present invention relates to indole derivatives or benzimidazole derivatives, to processes for preparing such compounds, to pharmaceutical compositions comprising such compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of I&#x3ba;B kinase comprising administering such compounds.

Indole derivatives or benzimidazole derivatives for modulating IkB kinase

The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C-C)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.

Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV

The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.

Amide-substituted 8-N-benzimidazoles, method for the production thereof, and use of the same as medicaments

The present invention comprises the use of amino-carbonyl-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes, carbohydrate and lipid metabolic disorders and other blood sugar complications.

Aminocarbonyl-substituted 8-N-benzimidazoles, methods for their preparation and their use in pharmaceutical compositions

Amino-substituted 8-N-benzimidazoles and methods for their use in blood sugar disorders

The present invention involves substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are defined herein. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds and methods for the treatment of metabolic disorders such as type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerosis diseases and the like through the administration of said compositions.

Substituted, bicyclic 8-pyrrolidinoxanthines, and methods for their use as inhibitors of dipeptidyl peptidase

Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed which are inhibitors of the enzyme dipeptidyl peptidase IV (DDP-IV) and comprise novel substituted bicyclic 8-pyrrolidinoxanthines of formula I and their derivatives: wherein the various R-groups are defined herein. These compounds may be combined with other secondary active compounds which also are effective in the treatment of said disorders and the disease states or physiological manifestations arising therefrom.

Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes

Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula I: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.

Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use

The present invention comprises the substituted 2-aminoalkylthiobenzimidazoles of formula I wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the treatment of type-2 diabetes.

Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use

The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.

Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use

Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.

Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R', R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use

One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use

Growing community of inventors

Frankfurt-am-Main, Germany

Gerhard Jaehne